0 10 Phenotypic phenotypic JJ 11 14 and and CC 15 25 functional functional JJ 26 33 studies study NNS 34 36 of of IN 37 47 leukocytes leukocyte NNS 48 50 in in IN 51 56 human human JJ 57 68 endometrium endometrium NN 69 72 and and CC 73 86 endometriosis endometriosis NN 86 87 . . . 89 92 The the DT 93 102 aetiology aetiology NN 103 105 of of IN 106 119 endometriosis endometriosis NN 119 120 , , , 121 122 a a DT 123 129 common common JJ 130 133 and and CC 134 143 disabling disable VBG 144 152 disorder disorder NN 152 153 , , , 154 156 is be VBZ 157 166 presently presently RB 167 174 unknown unknown JJ 174 175 , , , 176 184 although although IN 185 191 immune immune JJ 192 203 dysfunction dysfunction NN 204 209 could could MD 210 215 allow allow VB 216 223 ectopic ectopic JJ 224 235 endometrial endometrial JJ 236 245 fragments fragment NNS 246 248 to to TO 249 256 survive survive VB 257 264 outside outside IN 265 268 the the DT 269 276 uterine uterine JJ 277 283 cavity cavity NN 283 284 . . . 285 290 These these DT 291 298 studies study NNS 299 310 investigate investigate VBP 311 314 the the DT 315 327 relationship relationship NN 328 335 between between IN 336 345 leukocyte leukocyte NN 346 357 populations population NNS 357 358 , , , 359 366 steroid steroid NN 367 374 hormone hormone NN 375 383 receptor receptor NN 384 394 expression expression NN 394 395 , , , 396 409 proliferative proliferative JJ 410 418 activity activity NN 418 419 , , , 420 425 bcl-2 bcl-2 NN 426 436 expression expression NN 437 440 and and CC 441 450 apoptosis apoptosis NN 451 453 in in IN 454 461 eutopic eutopic JJ 462 465 and and CC 466 473 ectopic ectopic JJ 474 485 endometrium endometrium NN 486 490 from from IN 491 496 women woman NNS 497 501 with with IN 502 515 endometriosis endometriosis NN 516 518 or or CC 519 530 adenomyosis adenomyosis NN 531 533 at at IN 534 543 different different JJ 544 550 phases phase NNS 551 553 of of IN 554 557 the the DT 558 567 menstrual menstrual JJ 568 573 cycle cycle NN 573 574 . . . 575 588 Significantly significantly RB 589 598 increased increase VBN 599 608 oestrogen oestrogen NN 609 617 receptor receptor NN 618 628 expression expression NN 628 629 , , , 630 635 bcl-2 bcl-2 NN 636 646 expression expression NN 647 650 and and CC 651 658 numbers number NNS 659 661 of of IN 662 666 CD8+ cd8+ JJ 667 677 leukocytes leukocyte NNS 678 682 were be VBD 683 688 found find VBN 689 691 in in IN 692 699 ectopic ectopic JJ 700 708 compared compare VBN 709 713 with with IN 714 721 eutopic eutopic JJ 722 733 endometrium endometrium NN 734 736 in in IN 737 750 endometriosis endometriosis NN 750 751 , , , 752 755 and and CC 756 761 CD56+ cd56+ JJ 762 773 endometrial endometrial JJ 774 784 granulated granulate VBN 785 796 lymphocytes lymphocyte NNS 797 798 ( ( ( 798 802 eGLs egl NNS 802 803 ) ) ) 804 808 were be VBD 809 822 significantly significantly RB 823 830 reduced reduce VBN 831 833 in in IN 834 841 ectopic ectopic JJ 842 853 endometrium endometrium NN 853 854 . . . 855 864 Apoptotic apoptotic JJ 865 870 cells cell NNS 871 875 were be VBD 876 882 rarely rarely RB 883 888 found find VBN 889 891 in in IN 892 899 control control NN 900 903 and and CC 904 911 subject subject NN 912 922 endometria endometria NN 922 923 . . . 924 926 In in IN 927 935 contrast contrast NN 936 940 with with IN 941 954 endometriosis endometriosis NN 954 955 , , , 956 967 adenomyotic adenomyotic JJ 968 975 lesions lesion NNS 976 982 showed show VBD 983 992 identical identical JJ 993 1000 steroid steroid NN 1001 1008 hormone hormone NN 1009 1017 receptor receptor NN 1018 1028 expression expression NN 1028 1029 , , , 1030 1043 proliferative proliferative JJ 1044 1052 activity activity NN 1052 1053 , , , 1054 1059 bcl-2 bcl-2 NN 1060 1070 expression expression NN 1071 1074 and and CC 1075 1084 leukocyte leukocyte NN 1085 1099 subpopulations subpopulation NNS 1100 1102 to to TO 1103 1110 eutopic eutopic JJ 1111 1122 endometrium endometrium NN 1122 1123 , , , 1124 1134 indicating indicate VBG 1135 1144 different different JJ 1145 1156 aetiologies aetiology NNS 1157 1160 for for IN 1161 1166 these these DT 1167 1176 disorders disorder NNS 1176 1177 . . . 1178 1181 The the DT 1182 1189 unusual unusual JJ 1190 1195 CD56+ cd56+ JJ 1196 1201 CD16- cd16- JJ 1202 1206 eGLs egl NNS 1207 1214 present present JJ 1215 1217 in in IN 1218 1223 large large JJ 1224 1231 numbers number NNS 1232 1234 in in IN 1235 1239 late late JJ 1240 1249 secretory secretory JJ 1250 1255 phase phase NN 1256 1263 eutopic eutopic JJ 1264 1275 endometrium endometrium NN 1276 1280 were be VBD 1281 1287 highly highly RB 1288 1296 purified purify VBN 1297 1298 ( ( ( 1298 1301 >98 >98 CD 1301 1302 % % NN 1302 1303 ) ) ) 1304 1306 by by IN 1307 1321 immunomagnetic immunomagnetic JJ 1322 1332 separation separation NN 1332 1333 . . . 1334 1340 Except except IN 1341 1344 for for IN 1345 1346 a a DT 1347 1357 negligible negligible JJ 1358 1367 cytotoxic cytotoxic JJ 1368 1376 activity activity NN 1377 1379 of of IN 1380 1384 eGLs egl NNS 1385 1389 from from IN 1390 1395 early early JJ 1396 1409 proliferative proliferative JJ 1410 1417 samples sample NNS 1417 1418 , , , 1419 1428 cytotoxic cytotoxic JJ 1429 1437 activity activity NN 1438 1440 of of IN 1441 1445 eGLs egl NNS 1446 1450 from from IN 1451 1463 non-pregnant non-pregnant JJ 1464 1475 endometrium endometrium NN 1476 1482 during during IN 1483 1486 the the DT 1487 1496 menstrual menstrual JJ 1497 1502 cycle cycle NN 1503 1506 was be VBD 1507 1517 comparable comparable JJ 1518 1522 with with IN 1523 1528 those those DT 1529 1531 in in IN 1532 1542 peripheral peripheral JJ 1543 1548 blood blood NN 1548 1549 , , , 1550 1563 predominantly predominantly RB 1564 1569 CD56+ cd56+ JJ 1570 1575 CD16+ cd16+ JJ 1576 1583 natural natural JJ 1584 1590 killer killer NN 1591 1597 cells. cells. NNS 1598 1602 eGLs egl NNS 1603 1607 from from IN 1608 1620 non-pregnant non-pregnant JJ 1621 1632 endometrium endometrium NN 1633 1636 and and CC 1637 1642 early early JJ 1643 1652 pregnancy pregnancy NN 1653 1659 showed show VBD 1660 1661 a a DT 1662 1670 variable variable JJ 1671 1684 proliferative proliferative JJ 1685 1693 response response NN 1694 1696 to to TO 1697 1698 5 5 CD 1699 1702 and and CC 1703 1706 100 100 CD 1707 1711 U/ml u/ml NN 1712 1725 interleukin-2 interleukin-2 NN 1726 1730 over over IN 1731 1735 48-h 48-h JJ 1736 1739 and and CC 1740 1745 120-h 120-h JJ 1746 1750 time time NN 1751 1759 courses. courses. NN 1760 1764 eGLs egl NNS 1765 1768 are be VBP 1769 1778 evidently evidently RB 1779 1791 functionally functionally RB 1792 1801 important important JJ 1802 1804 in in IN 1805 1808 the the DT 1809 1816 eutopic eutopic JJ 1817 1828 endometrium endometrium NN 1828 1829 . . . 1830 1835 Their their PRP$ 1836 1843 absence absence NN 1844 1846 in in IN 1847 1860 endometriotic endometriotic JJ 1861 1868 lesions lesion NNS 1869 1877 together together RB 1878 1882 with with IN 1883 1892 increased increase VBN 1893 1897 CD+8 cd+8 NN 1898 1904 T-cell t-cell NN 1905 1912 numbers number NNS 1913 1916 and and CC 1917 1926 increased increase VBN 1927 1936 oestrogen oestrogen NN 1937 1945 receptor receptor NN 1946 1949 and and CC 1950 1955 bcl-2 bcl-2 NN 1956 1966 expression expression NN 1967 1970 may may MD 1971 1975 have have VB 1976 1987 significant significant JJ 1988 1995 effects effect NNS 1996 1998 on on IN 1999 2002 the the DT 2003 2014 development development NN 2015 2018 and and CC 2019 2030 progression progression NN 2031 2033 of of IN 2034 2047 endometriosis endometriosis NN 2047 2048 . . .